Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 270 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... May 24, 2023 Oncotype DX Breast Cancer Test May Be Less Accurate for Black... February 26, 2021 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales April 1, 2021 EMA Recommends Granting a Marketing Authorisation for Tucatinib December 22, 2020 Load more HOT NEWS Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... Heartburn Medications Pulled From Shelves Because They May Cause Cancer ¿Las gammagrafías óseas muestran el cáncer? A New FDA Approval Furthers the Role of Genomics in Cancer...
